Please use this identifier to cite or link to this item:
Title: A child with resistant Kawasaki disease successfully treated with anakinra: a case report
Author: Sánchez Manubens, J
Gelman, A.
Franch, N.
Teodoro, S.
Palacios, J. R.
Rudi, N.
Rivera, J.
Antón López, Jordi
Keywords: Vasculitis
Infants malalts
Sick children
Issue Date: 8-Apr-2017
Publisher: BioMed Central
Abstract: Background: Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology. Intravenous immunoglobulin (IVIG) is an effective treatment and decreases the risk of cardiac complications to less than 5%. In spite of its effectiveness, some children do not respond to this therapy and still develop coronary aneurysms (CAA). The optimal treatment for IVIG non-responsive patients remains controversial although corticoids have been suggested to be an effective treatment in some patients. For those patients still resistant to IVIG and corticoids, interleukin-1 receptor antagonists (IL-1RA) such anakinra could be an alternative. Case presentation: We present a 3 year-old Caucasian patient with KD without cardiac complications but with important resistance to treatment. After becoming resistant to IVIG and corticoids, anakinra proved to be an effective treatment. Conclusions: To our knowledge, this is the first report of the utility of IL-1RA in refractory KD without coronary impairment. The patient fulfilled the classical criteria for KD and, after becoming resistant to first and second line treatments, anakinra proved to be an effective treatment. Further studies are required to determine if this is an effective treatment option for other cases of resistant Kawasaki disease.
Note: Reproducció del document publicat a:
It is part of: BMC Pediatrics, 2017, vol. 17, num. 102
Related resource:
ISSN: 1471-2431
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Files in This Item:
File Description SizeFormat 
671809.pdf337.58 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons